|
|
|
市場調査レポート
州の活動が米国の医薬品業界に及ぼす影響
State Activities: Impact on the U.S. Pharmaceutical Industry
|
当商品の販売は、2011年12月21日を持ちまして終了しました。
Abstract
Introduction
In 2005, 17% of the nation' s $2 trillion in health care costs was paid by
state and local governments, including more than $21.7 billion for
prescription drugs; these costs are expected to double over the next ten
years. Determined to protect state budgets without cutting essential health
care services, state legislatures are enacting laws intended to lower drug
costs by regulating the health care and prescription drug industries.
Get the Answers You Need to Shape Your Strategy
As drug costs continue to rise, state legislatures become increasingly
proactive, enacting legislation intended to contain costs and to create new
kinds of local health care initiatives-and taking legal action against
pharmaceutical companies over issues of drug pricing and safety. Can
pharmaceutical companies turn this situation around? How can companies adjust
their marketing strategies to the requirements of increasingly vigilant
national and state governments? In the current environment of distrust, are
there opportunities for companies to build mutually benefi cially
relationships with the states? In the proliferation of state initiatives in
many areas of health care, are there any that may benefi t pharmaceutical
companies?
Scope
- Issues addressed by state legislatures: drug pricing, drug
reimportation, patient/prescriber privacy, electronic medical records, stem
cell funding, life sciences research, HPV vaccination, universal health care
- 2007 state legislation: most active states, bills fi led, most
frequently targeted pharmaceutical-related issues
- Programs initiated by states: evidence-based medicine initiatives,
Pennsylvania PACE Program, Oregonbased Drug Effectiveness Review Project, the
Prescription Project, child health insurance programs, drug purchase
assistance, state-funded life sciences research initiatives
- Prescription data protection: New Hampshire prescription
information law, AMA prescribing data restriction program
- Electronic health records: State Alliance for e-health, individual
state initiatives, National Health Information Network
- State legal actions against pharmaceutical companies: companies
targeted, plaintiff states, nature of complaints, settlements awarded
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- State Legislatures Taking Action Against Serious Drug Concerns
- 2007 State Legislative Bills
- Northern States Push for Drug Reimportation
- Political Maneuverings Create “Poison Pills”
- Vested Interests: Politicians, Lobbyists, and Patients
- Effects of Looming Presidential and Congressional Elections
- Battle Lines Drawn Over Access to Prescriber-Identifi able Prescription
Data
- New Hampshire' s Prescription Information Law
- AMA National Prescribing Data Restriction Program
- Electronic Health Records-Interoperability, Transparency, and
Accountability for All
- National Health Information Network
- State Alliance for e-Health
- State Attorneys General Not Afraid to Litigate
- State Antitrust Enforcement
- Average Wholesale Price Manipulations and State Litigation
- Educating Physicians: Evidence-Based Medicine and Counter-Detailing
- Pennsylvania' s PACE Program
- The Drug Effectiveness Review Project
- The Prescription Project
- States Are Funding Research That Benefi ts the Pharma Industry
- Economic Development Through State Life Sciences Initiatives
- Stem Cell Funding Initiatives
- Access to Affordable Medicines
- State Children' s Health Insurance Program
- State Pharmaceutical Assistance Programs
- States Push for Generics
- Industry' s Helping Hand
- Mandatory Human Papillomavirus Vaccine Legislation
- Just Another Cancer Drug or First-Ever Vaccine?
- A New Challenge for Pharmaceutical Companies
- State-Sponsored Universal Health Care
- States Taking the Lead on Universal Health Care
- Businesses Attempt Health Care Reform
- Capturing the Future
Figures
- 1. Factors Contributing to Total Prescription Drug Spending Growth,
1988-2016
- 2. United States Expenditures on Prescription Drugs, 2000, 2005, and 2016
- 3. Prescription Drug State Legislation, 2007
- 4. Drug Reimportation Timeline: Politics, Patients' Rights, and
Pharmaceutical Industry Lobbying
- 5. Timeline of Select Stem Cell Research Activities in Different States,
2000-2007
- 6. SCHIP Funds: Allocation Versus Spending, 1998-2007
- 7. State Pharmaceutical Assistance Programs, 2006
- 8. Health Insurance Premiums, Percentage Increase, 1996-2006
- 9. Status of State Initiatives for Health Care Reform
Sidebars
- New Hampshire House Bill 1346-An Act requiring certain persons to keep the
contents of prescriptions confi dential (excerpt)
- Human Papillomavirus, Cancer, and Sexually Transmitted Disease
Tables
- 1. State e-Health Initiatives-Channels for Creating Health Information
Technology Networks, 2007
- 2. States Take Legal Action Against Pharmaceutical Companies
- 3. Relative Advantages of Life Sciences Clusters in Three States, 2002
- Appendix-State Drug Assistance Programs, 2007
|
 |
